We also observed higher expression of Pirh2 in patients with newly diagnosed MM than in patients with relapsed MM treated with bortezomib-based therapies, indicating that MM patients with low Pirh2 levels were refractory to bortezomib. Here, RCHY1 is linked to Miyoshi myopathy.